Cancer Research UK logo.
SearchDonate
  • Search

A trial looking at vandetanib and fulvestrant and for breast cancer that has become resistant to hormone therapy (FURVA)

Overview

Cancer types:

Breast cancer

Status:

Closed

Phase:

Phase 2

Details

This trial is looking at a drug called vandetanib alongside a type of hormone therapy drug called fulvestrant. It is for post menopausal women with breast cancer that has spread into tissue surrounding the breast (is locally advanced) or to another part of the body and has receptors for the hormone oestrogen (is ER positive). This trial is supported by Cancer Research UK.

Recruitment start: 20 April 2015

Recruitment end: 31 October 2017

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Dr Mark Beresford Dr Robert Jones

Supported by

AstraZeneca

Cancer Research UK

Experimental Cancer Medicine Centre (ECMC)

NIHR Clinical Research Network: Cancer

Velindre NHS Trust

Other information

This is Cancer Research UK trial number CRUK/13/029

Last reviewed: 31 Oct 2017

CRUK internal database number: 11760

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Questions for your doctor

What to ask your doctor about clinical trials.

An icon of two speech bubbles, indicating a conversation.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.